Products

Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.

Connect With Us

All Products (882)

Quick filters: Solid Tumour Hematologic Both Name A-Z Name Z-A

Therapeutic Areas

Sort by

Molecule	Drug Class / Mechanism	Oncology Type
Simtuzumab	Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase)	Solid Tumour
Molecule Simtuzumab Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase)
Tarextumab	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Tarextumab Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Tarlatamab	Costimulatory / Bispecific Agent	Solid Tumour
Molecule Tarlatamab Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent
Telaglenastat	Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase)	Solid Tumour
Molecule Telaglenastat Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase)
Teplizumab (Onc Adjacent)	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Teplizumab (Onc Adjacent) Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Tiragolumab	TIGIT Inhibitor	Solid Tumour
Molecule Tiragolumab Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Solid Tumour Drug Class / Mechanism TIGIT Inhibitor
Toremifene Citrate	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Toremifene Citrate Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Tozasertib	Polo-Like / Aurora Kinase Inhibitor	Both (Solid & Hematologic)
Molecule Tozasertib Therapeutic Category Targeted Therapy (Investigational) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Polo-Like / Aurora Kinase Inhibitor
Trastuzumab Rezetecan	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Trastuzumab Rezetecan Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Trebananib	Investigational Monoclonal / ADC Agent	Solid Tumour
Molecule Trebananib Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
TTI-621 (Cibisatamab-related)	CD47 (Macrophage Checkpoint) Inhibitor	Hematologic
Molecule TTI-621 (Cibisatamab-related) Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Tulmimetostat	Dual EZH2/EZH1 Inhibitor	Both (Solid & Hematologic)
Molecule Tulmimetostat Therapeutic Category Targeted Therapy (Investigational) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Dual EZH2/EZH1 Inhibitor

Simtuzumab Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase)
Tarextumab Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Tarlatamab Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Costimulatory / Bispecific Agent
Telaglenastat Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Solid Tumour Drug Class / Mechanism Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase)
Teplizumab (Onc Adjacent) Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Tiragolumab Immunotherapy (Investigational Checkpoint)
Therapeutic Category Immunotherapy (Investigational Checkpoint) Oncology Type Solid Tumour Drug Class / Mechanism TIGIT Inhibitor
Toremifene Citrate Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Tozasertib Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Polo-Like / Aurora Kinase Inhibitor
Trastuzumab Rezetecan Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
Trebananib Targeted Therapy (Investigational Antibody / ADC)
Therapeutic Category Targeted Therapy (Investigational Antibody / ADC) Oncology Type Solid Tumour Drug Class / Mechanism Investigational Monoclonal / ADC Agent
TTI-621 (Cibisatamab-related) Immunotherapy (Investigational)
Therapeutic Category Immunotherapy (Investigational) Oncology Type Hematologic Drug Class / Mechanism CD47 (Macrophage Checkpoint) Inhibitor
Tulmimetostat Targeted Therapy (Investigational)
Therapeutic Category Targeted Therapy (Investigational) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Dual EZH2/EZH1 Inhibitor

‹ 1 … 70 71 72 73 74 ›

Product Range

Company

Global Network

Products

All Products (882)

Simtuzumab

Tarextumab

Tarlatamab

Telaglenastat

Teplizumab (Onc Adjacent)

Tiragolumab

Toremifene Citrate

Tozasertib

Trastuzumab Rezetecan

Trebananib

TTI-621 (Cibisatamab-related)

Tulmimetostat

Simtuzumab

Tarextumab

Tarlatamab

Telaglenastat

Teplizumab (Onc Adjacent)

Tiragolumab

Toremifene Citrate

Tozasertib

Trastuzumab Rezetecan

Trebananib

TTI-621 (Cibisatamab-related)

Tulmimetostat